0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Questions and Answers

JAMA. 1991;265(24):3321-3323. doi:10.1001/jama.1991.03460240119048.
Text Size: A A A
Published online

Extract

The categories for response to a DATTA question are defined as follows: Established—this technology has been adequately evaluated and its (A) safety or (B) effectiveness is accepted as appropriate by the practicing medical community for the given indication in the specified patient population; Promising— given current knowledge, the (A) safety or (B) effectiveness of this technology is appropriate for the given indication in the specified patient population; Investigational—there is no consensus on the (A) safety or (B) effectiveness of this technology to date, there is insufficient evidence to determine its appropriateness, or it warrants further study; use of this technology for the given indication in the specified patient population should be confined largely to research protocols; Doubtful—given current knowledge, the (A) safety or (B) effectiveness of this technology is inappropriate for the given indication in the specified patient population; and Unacceptable—the (A) safety or (B) effectiveness of this technology is regarded by the practicing medical community as inappropriate for the given indication in the specified patient population.
For each question, any response category receiving 50% or more of the panel's votes was tested for a consensus by assuming that the DATTA panel is a sample from a broader population of experts. Using exact binomial probabilities, the likelihood of the observed vote was calculated if exactly 50% of the total population of experts support that response for that question. Hence, the null hypothesis is 50% of all experts support the response, and the alternative, one-tailed hypothesis is that more than 50% of all experts support the response. Rejection of the null hypothesis, and acceptance of the alternative, is interpreted as evidence of a majority opinion in the total population of experts, and a consensus is achieved. If no consensus was found, the categories were reorganized and reanalyzed. The concept "appropriate" includes the categories "promising" and "established," while the concept "inappropriate" includes the categories "doubtful" and "unacceptable." The original five categories were thus, if necessary, reorganized into three categories, "appropriate," "investigational," and "inappropriate"; an analysis of any category with 50% or more of the vote was performed. P values for the survey responses are as follows: question A, 19 "appropriate" responses out of 23, P =.0013 consensus for appropriate; question B, 21 "appropriate" responses out of 23, P<.0001, consensus for appropriate. Eleven panelists offered no opinion for questions A and B.
 Vasoactive intracavernous pharmacotherapy for impotence: papaverine and phentolamine . JAMA. 1990;264:752-754. Diagnostic and Therapeutic Technology Assessment.
Link to Article[[XSLOpenURL/10.1001/jama.1990.03450060098041]]
Stackl W, Hasun R, Marberger M.  Intracavernous injection of prostaglandin E, in impotent men . J Urol. 1988;140:66-68.
Waldhauser M, Schramek P.  Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction . J Urol. 1988;140:525-527.
Sarosdy MF, Hudnall CH, Erickson DR, Hardin TC, Novicki DE.  A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E, in the treatment of impotence . J Urol. 1989;141:551-553.
Lee LM, Stevenson RW, Szasz G.  Prostaglandin E, versus phentolamine/ papaverine for treatment of erectile impotence: a double-blind comparison . J Urol. 1989;141:549-550.
Ishii N, Watanabe H, Irisawa C, et al.  Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence . J Urol. 1989;141:323-325.
Earle CM, Keogh EJ, Wisniewski ZS, et el.  Prostaglandin E1 therapy for impotence: comparison with papaverine . J Urol. 1990;143:57-59.
Floth A, Schramek P.  Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone . J Urol. 1991;145:56-59.
Gerrard JM. Prostaglandins and Leukotrienes . New York, NY: Marcel Dekker Inc; 1985.
Drug Evaluations Subscription . Chicago, Ill: American Medical Association; 1990;2( (9) ):1-2.
Langer SZ.  Presynaptic regulation of the release of catecholamines . Pharmacol Rev. 1981;32:337-340.
Heymann MA.  Pharmacologic use of prostaglandin E1 in infants with congenital heart disease . Am Heart J. 1981;101:837-843.
Link to Article[[XSLOpenURL/10.1016/0002-8703(81)90622-0]]
Klinge E, Sjostrand ND.  Comparative study of some isolated mammalian smooth muscle effectors of penile erection . Acta Physiol Scand. 1977;100:354-367.
Link to Article[[XSLOpenURL/10.1111/apha.1977.100.issue-3]]
Hamberg M.  Biosynthesis of prostaglandin E1 by human seminal vesicles . Lipids. 1976;11:249-250.
Link to Article[[XSLOpenURL/10.1007/BF02532867]]
Roy AC, Tan SM, Kottegoda SR, Ratman SS.  Ability of human corpora cavernosa muscle to generate prostaglandins and thromboxanes in vitro . IRCS J Med Sci. 1984;12:608-609.
Jeremy JY, Morgan RJ, Mikhailidis DP, Dandona P.  Prostacyclin synthesis by the corpora cavernosa of the human penis: evidence for muscarine control and pathologic implications . Prostaglandins Leukot Med. 1986;23:211-214.
Link to Article[[XSLOpenURL/10.1016/0262-1746(86)90188-5]]
Hedlund H, Andersson KE.  Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery . J Urol. 1985;134:1245-1250.
Virag R.  Intracavernous injection of papaverine for erectile failure . Lancet. 1982;2:938.
Link to Article[[XSLOpenURL/10.1016/S0140-6736(82)90910-2]]
Virag R, Adaikan PG.  Effects of prostaglandin E1 on penile erection and erectile failure . J Urol. 1987;137:1010.
Reiss H.  Use of prostaglandin E, for papaverine-failed erections . Urology. 1989;33:15-16.
Link to Article[[XSLOpenURL/10.1016/0090-4295(89)90058-7]]
Schramek P, Dorninger R, Waldhauser M, Konecny P, Porpaczy P.  Prostaglandin E, in erectile dysfunction: efficiency and incidence of priapism . Br J Urol. 1990;65:68-71.
Link to Article[[XSLOpenURL/10.1111/bju.1990.65.issue-1]]
Aboseif SR, Breza J, Bosca RJLH, et al.  Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates . J Urol. 1989;142:403-408.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();